778 related articles for article (PubMed ID: 10525372)
1. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy.
Han X; Wilbanks GD; Devaja O; Ruperelia V; Raju KS
Gynecol Oncol; 1999 Nov; 75(2):198-210. PubMed ID: 10525372
[TBL] [Abstract][Full Text] [Related]
2. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
3. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
4. Adoptive cellular immunotherapy of human ovarian carcinoma xenografts in nude mice.
Ortaldo JR; Porter HR; Miller P; Stevenson HC; Ozols RF; Hamilton TC
Cancer Res; 1986 Sep; 46(9):4414-9. PubMed ID: 3089592
[TBL] [Abstract][Full Text] [Related]
5. Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy.
Andreesen R; Scheibenbogen C; Brugger W; Krause S; Meerpohl HG; Leser HG; Engler H; Löhr GW
Cancer Res; 1990 Dec; 50(23):7450-6. PubMed ID: 1701343
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
[TBL] [Abstract][Full Text] [Related]
7. [Clinical application of adoptive immunotherapy by cytotoxic T lymphocytes induced from tumor-infiltrating lymphocytes].
Yamaue H; Tanimura H; Tsunoda T; Iwahashi M; Tani M; Inoue M; Tamai M
Nihon Gan Chiryo Gakkai Shi; 1990 May; 25(5):978-89. PubMed ID: 2391445
[TBL] [Abstract][Full Text] [Related]
8. Tumor lymphocytes in patients with advanced ovarian cancer: changes during in vitro culture and implications for immunotherapy.
Han X; Papadopoulos AJ; Ruparelia V; Devaja O; Raju KS
Gynecol Oncol; 1997 Jun; 65(3):391-8. PubMed ID: 9190963
[TBL] [Abstract][Full Text] [Related]
9. Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19 (NKH1)-positive recombinant IL-2-activated cultures of lymphocytes infiltrating human ovarian tumors.
Heo DS; Whiteside TL; Kanbour A; Herberman RB
J Immunol; 1988 Jun; 140(11):4042-9. PubMed ID: 3286766
[TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells.
Allavena P; Peccatori F; Maggioni D; Erroi A; Sironi M; Colombo N; Lissoni A; Galazka A; Meiers W; Mangioni C
Cancer Res; 1990 Nov; 50(22):7318-23. PubMed ID: 2121337
[TBL] [Abstract][Full Text] [Related]
11. Induction of immunocellular resistance to IL-2-activated lymphocytes within ovarian carcinoma cells.
Papadopoulos AJ; Han X; Matossian-Rogers A; Raju KS
Gynecol Oncol; 1995 Jun; 57(3):388-94. PubMed ID: 7774843
[TBL] [Abstract][Full Text] [Related]
12. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic effects of T cells induced by fusion protein 6B11-pulsed dendritic cells on ovarian carcinoma cells.
Yang W; Feng J; Chang X; Fu T; Ye X; Zhang H; Li X; Wen H; Feng L; Tong C; Cui H
Gynecol Oncol; 2007 Apr; 105(1):238-43. PubMed ID: 17383546
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of monoclonal antibodies specific for macrophages at intermediate stages in the tumoricidal activation pathway.
Paulnock DM; Lambert LE
J Immunol; 1990 Jan; 144(2):765-73. PubMed ID: 2104906
[TBL] [Abstract][Full Text] [Related]
15. Non-cytotoxic and sublethal paclitaxel treatment potentiates the sensitivity of cultured ovarian tumor SKOV-3 cells to lysis by lymphokine-activated killer cells.
Law KS; Chen HC; Liao SK
Anticancer Res; 2007; 27(2):841-50. PubMed ID: 17465210
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
[TBL] [Abstract][Full Text] [Related]
17. Large-scale production of human tumorcytotoxic macrophages grown from blood monocytes of cancer patients.
Brugger W; Scheibenbogen C; Krause S; Andreesen R
Cancer Detect Prev; 1991; 15(5):407-12. PubMed ID: 1751952
[TBL] [Abstract][Full Text] [Related]
18. Interferon effect on cytotoxicity of peripheral blood and tumor-associated lymphocytes against human ovarian carcinoma cells.
Allavena P; Introna M; Sessa C; Mangioni C; Mantovani A
J Natl Cancer Inst; 1982 Apr; 68(4):555-62. PubMed ID: 6175786
[TBL] [Abstract][Full Text] [Related]
19. Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer.
Nagamine I; Yamaguchi Y; Ohara M; Ikeda T; Okada M
Hiroshima J Med Sci; 2009 Mar; 58(1):37-44. PubMed ID: 19400555
[TBL] [Abstract][Full Text] [Related]
20. Innate-immune therapy for lung carcinoma based on tissue-macrophage activation with lipopolysaccharide.
Hino M; Kohchi C; Nishizawa T; Yoshida A; Nakata K; Inagawa H; Hori H; Makino K; Terada H; Soma G
Anticancer Res; 2005; 25(6A):3747-54. PubMed ID: 16302735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]